Perceptive Advisors LLC
In its 13F for Q2 2024 (holdings as of June 30, 2024, filed August 16, 2024), Perceptive Advisors LLC reported 104 stock positions worth $4.1 billion. Its top holding was Cerevel Therapeutics (CERE) at 10.7% of the portfolio, followed by Amicus Therapeutics (FOLD, 6.7%) and Arcellx (ACLX, 5.2%). Compared with Q1 2024, it opened 19 new positions, sold out of 17, added to 20 and reduced 30. The biggest buy was Intra-Cellular Therapies (ITCI, shares +63%) and the biggest sale an exit from Fusion Pharmaceuticals (FUSN).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001224962
- Portfolio Value
- $4.1B (Q2 2024)
- SEC Filing
- 0001012975-24-000346 ↗ filed Aug 16, 2024
Holdings Value
Holdings 104 stocks · $4.1B
| CERE Cerevel Therapeutics Holding | 10.65% | 10,794,876 | $441.4M | No change |
| FOLD Amicus Therapeutics Inc. | 6.72% | 28,057,456 | $278.3M | No change |
| ACLX Arcellx Inc. | 5.18% | 3,889,739 | $214.7M | Reduce -1.1% |
| IOVA Iovance Biotherapeutics Inc. | 5.02% | 25,933,142 | $208.0M | Add +34.6% |
| NUVL Nuvalent Inc. Class A | 4.67% | 2,549,077 | $193.4M | Reduce -8.4% |
| RYTM Rhythm Pharmaceuticals Inc. | 3.42% | 3,446,579 | $141.5M | Add +5.5% |
| PCVX Vaxcyte Inc. | 3.39% | 1,862,608 | $140.6M | Reduce -3.6% |
| SLNO Soleno Therapeutics Inc. | 3.16% | 3,204,976 | $130.8M | Add +4.2% |
| ITCI Intra-Cellular Therapies Inc. | 2.84% | 1,716,407 | $117.6M | Add +62.6% |
| IMTX Immatics NV | 2.27% | 8,086,159 | $94.0M | Add +76.5% |
| NBIX Neurocrine Biosciences Inc. | 2.16% | 649,909 | $89.5M | Reduce -19.2% |
| APGE Apogee Therapeutics Inc. | 2.00% | 2,105,636 | $82.9M | Add +2.2% |
| MDGL Madrigal Pharmaceuticals Inc. | 1.79% | 264,600 | $74.1M | Reduce -38.5% |
| AORT Artivion Inc. | 1.73% | 2,793,703 | $71.7M | Add +4.7% |
| SYRE Spyre Therapeutics Inc. | 1.72% | 3,031,018 | $71.3M | Add +18.6% |
| CRNX Crinetics Pharmaceuticals Inc. | 1.60% | 1,476,203 | $66.1M | No change |
| EOLS Evolus Inc. | 1.51% | 5,753,798 | $62.4M | No change |
| SWTX Springworks Therapeutics Inc. | 1.50% | 1,652,962 | $62.3M | Reduce -26.9% |
| CRGX Cargo Therapeutics Inc. | 1.46% | 3,683,004 | $60.5M | Add +6.8% |
| ATXS Astria Therapeutics Inc. | 1.42% | 6,485,420 | $59.0M | No change |
| NTRA Natera Inc. | 1.39% | 530,000 | $57.4M | Reduce -30.0% |
| VRCA Verrica Pharmaceuticals Inc. | 1.25% | 7,099,182 | $51.8M | No change |
| BHVN Biohaven Ltd. | 1.24% | 1,485,232 | $51.6M | Reduce -13.9% |
| IMVT Immunovant Inc. | 1.23% | 1,923,786 | $50.8M | Reduce -35.1% |
| MGTX Meiragtx Holdings PLC | 1.15% | 11,331,103 | $47.7M | No change |
| PTGX Protagonist Therapeutics Inc. | 1.06% | 1,268,735 | $44.0M | Add +27.6% |
| SLDB Solid Biosciences Inc. | 0.95% | 6,906,646 | $39.2M | No change |
| CELC Celcuity Inc. | 0.93% | 2,362,279 | $38.7M | No change |
| MDT Medtronic PLC | 0.93% | 490,665 | $38.6M | Reduce -65.7% |
| VKTX Viking Therapeutics Inc. | 0.92% | 721,377 | $38.2M | Reduce -27.4% |
| APLT Applied Therapeutics Inc. | 0.90% | 8,005,000 | $37.4M | No change |
| AXSM Axsome Therapeutics Inc. | 0.89% | 459,111 | $37.0M | Reduce -58.5% |
| CNTA Centessa Pharmaceuticals Ltd. | 0.86% | 3,933,307 | $35.5M | Add +27.6% |
| TARS Tarsus Pharmaceuticals Inc. | 0.85% | 1,296,416 | $35.2M | No change |
| VRNA Verona Pharma Ltd. | 0.85% | 2,433,725 | $35.2M | Reduce -35.3% |
| AKRO Akero Therapeutics Inc. | 0.85% | 1,499,897 | $35.2M | Add +8.1% |
| EWTX Edgewise Therapeutics Inc. | 0.81% | 1,856,417 | $33.4M | Reduce -20.0% |
| ACRV Acrivon Therapeutics Inc. | 0.75% | 5,360,858 | $31.1M | Add +78.2% |
| PRAX Praxis Precision Medicines I | 0.75% | 750,230 | $31.0M | Reduce -8.7% |
| ADMA Adma Biologics Inc. | 0.75% | 2,771,000 | $31.0M | Reduce -56.9% |
| BBIO Bridgebio Pharma Inc. | 0.74% | 1,215,346 | $30.8M | Reduce -13.9% |
| ALDX Aldeyra Therapeutics Inc. | 0.74% | 9,275,851 | $30.7M | Add +7.9% |
| NAUT Nautilus Biotechnology Inc. | 0.71% | 12,594,211 | $29.5M | No change |
| CTNM Contineum Therapeutics Inc. Class A | 0.67% | 1,566,668 | $27.6M | New |
| ISRG Intuitive Surgical Inc. | 0.66% | 61,800 | $27.5M | Reduce -39.3% |
| ARVN Arvinas Inc. | 0.66% | 1,027,749 | $27.4M | Reduce -16.9% |
| RCKT Rocket Pharmaceuticals Inc. | 0.65% | 1,246,597 | $26.8M | Reduce -30.8% |
| IRON Disc Medicine Inc. | 0.60% | 553,437 | $24.9M | Reduce -41.1% |
| LIVN Livanova PLC | 0.59% | 444,000 | $24.3M | Add +48.5% |
| CGON CG Oncology Inc. | 0.56% | 733,695 | $23.2M | Reduce -43.7% |
| XENE Xenon Pharmaceuticals Inc. | 0.55% | 583,256 | $22.7M | Reduce -34.6% |
| OCUL Ocular Therapeutix Inc. | 0.55% | 3,324,468 | $22.7M | No change |
| PEPG Pepgen Inc. | 0.54% | 1,410,438 | $22.5M | No change |
| VRDN Viridian Therapeutics Inc. | 0.51% | 1,631,828 | $21.2M | Reduce -55.4% |
| OBIO Orchestra Biomed Holdings Inc. | 0.50% | 2,545,881 | $20.7M | No change |
| MRUS Merus NV | 0.43% | 300,000 | $17.8M | New |
| RAPP Rapport Therapeutics Inc. | 0.42% | 748,183 | $17.4M | New |
| TYRA Tyra Biosciences Inc. | 0.39% | 1,007,367 | $16.1M | Add +50.5% |
| INBX Inhibrx Biosciences Inc. | 0.36% | 1,064,026 | $15.1M | No change |
| ARQT Arcutis Biotherapeutics Inc. | 0.35% | 1,558,500 | $14.5M | Add +107.8% |
| ATHIRA PHARMA INC | 0.35% | 5,402,964 | $14.3M | No change |
| ZYME Zymeworks Inc. | 0.34% | 1,667,711 | $14.2M | Add +55.2% |
| CGEM Cullinan Therapeutics Inc. | 0.32% | 749,916 | $13.1M | New |
| PRCT Procept Biorobotics Corp. | 0.31% | 210,659 | $12.9M | No change |
| INSM Insmed Inc. | 0.29% | 180,000 | $12.1M | New |
| BCYC Bicycle Therapeutics PLC-ADR | 0.28% | 572,000 | $11.6M | New |
| ICLR Icon PLC | 0.24% | 31,250 | $9.8M | New |
| TEM Tempus AI Inc. Class A | 0.23% | 275,000 | $9.6M | New |
| AVBP Arrivent Biopharma Inc. | 0.19% | 415,000 | $7.7M | No change |
| ENGN Engene Holdings Inc. | 0.18% | 800,000 | $7.5M | Reduce -19.9% |
| SPRY Ars Pharmaceuticals Inc. | 0.18% | 867,319 | $7.4M | No change |
| ARGX Argenx SE - ADR | 0.16% | 15,600 | $6.7M | New |
| ALLO Allogene Therapeutics Inc. | 0.15% | 2,725,000 | $6.3M | New |
| VERU Veru Inc. | 0.14% | 7,063,277 | $5.9M | Add +26.5% |
| KALV Kalvista Pharmaceuticals Inc. | 0.14% | 500,000 | $5.9M | No change |
| RXRX Recursion Pharmaceuticals-A | 0.14% | 769,230 | $5.8M | New |
| EYPT Eyepoint Inc. | 0.13% | 640,274 | $5.6M | Add +8.6% |
| BBOT Bridgebio Oncology Therapeut filed as HELIX ACQUISITION CORP II | 0.12% | 500,000 | $5.1M | No change |
| MREO Mereo Biopharma Group PL-ADR | 0.11% | 1,253,250 | $4.5M | New |
| CABA Cabaletta Bio Inc. | 0.11% | 585,045 | $4.4M | Reduce -65.9% |
| DTIL Precision Biosciences Inc. | 0.10% | 426,293 | $4.1M | Reduce -11.3% |
| SKYE Skye Bioscience Inc. | 0.10% | 500,000 | $4.0M | New |
| TRINITY BIOTECH INVT LTD | 0.09% | 1,800,000 | $3.8M | No change |
| IRTC Irhythm Holdings Inc. | 0.09% | 35,205 | $3.8M | Reduce -85.6% |
| LYRA Lyra Therapeutics Inc. | 0.09% | 12,757,562 | $3.5M | No change |
| BDSX Biodesix Inc. | 0.08% | 2,173,880 | $3.3M | New |
| NVNO Envveno Medical Corporation | 0.08% | 623,315 | $3.3M | No change |
| FHTX Foghorn Therapeutics Inc. | 0.08% | 544,000 | $3.1M | New |
| NBTX Nanobiotix SA - ADR | 0.07% | 555,066 | $2.8M | No change |
| ABSI Absci Corp. | 0.05% | 700,000 | $2.2M | No change |
| XBI SS SPDR S&P Biotech ETF | 0.05% | 22,665 | $2.1M | New |
| XFOR X4 Pharmaceuticals Inc. | 0.05% | 3,545,454 | $2.1M | No change |
| FORTE BIOSCIENCES INC | 0.04% | 3,265,359 | $1.8M | No change |
| RVNC Revance Therapeutics Inc. | 0.04% | 600,000 | $1.5M | No change |
| GPCR Structure Therapeutics Inc. | 0.03% | 34,852 | $1.4M | New |
| FATE Fate Therapeutics Inc. | 0.03% | 345,575 | $1.1M | New |
| KYTX Kyverna Therapeutics Inc. | 0.03% | 150,000 | $1.1M | No change |
| EGRX Eagle Pharmaceuticals Inc. | 0.02% | 173,365 | $971K | New |
| VBIVQ Vbi Vaccines Inc. | 0.02% | 1,261,710 | $833K | No change |
| TCMD Tactile Systems Technology I | 0.02% | 62,639 | $748K | Reduce -93.1% |
| SYRS Syros Pharmaceuticals Inc. | 0.01% | 116,754 | $602K | No change |
| OMIC Singular Genomics Systems Inc. | 0.01% | 70,896 | $599K | No change |
| CMAXQ Caremax Inc. | 0.01% | 122,643 | $342K | No change |
| AXGN Axogen Inc. | 0.01% | 30,421 | $220K | Reduce -98.0% |
Options reported separately and not counted above: IMVT calls ($5.3M), FLNA puts ($2.3M), NVAX puts ($1.3M).
Other holdings (3): bonds, preferreds, convertibles and warrants · $29K (not counted above)
Total filed on the 13F, all lines: $4.1B.
Portfolio Sells Q1 2024 → Q2 2024
| FUSN Fusion Pharmaceuticals Inc. | Sold out | 0.00% | −2.56 |
| MDT Medtronic PLC | Reduce -65.7% | 0.93% | −1.26 |
| SRPT Sarepta Therapeutics Inc. | Sold out | 0.00% | −1.20 |
| AXSM Axsome Therapeutics Inc. | Reduce -58.5% | 0.89% | −0.66 |
| VRDN Viridian Therapeutics Inc. | Reduce -55.4% | 0.51% | −0.62 |
| LABP Landos Biopharma Inc. | Sold out | 0.00% | −0.56 |
| TMCI Treace Medical Concepts Inc. | Sold out | 0.00% | −0.53 |
| VKTX Viking Therapeutics Inc. | Reduce -27.4% | 0.92% | −0.51 |
| AUTL Autolus Therapeutics PLC | Sold out | 0.00% | −0.49 |
| IMVT Immunovant Inc. | Reduce -35.1% | 1.23% | −0.46 |
| SWTX Springworks Therapeutics Inc. | Reduce -26.9% | 1.50% | −0.46 |
| CGON CG Oncology Inc. | Reduce -43.7% | 0.56% | −0.45 |
| IRON Disc Medicine Inc. | Reduce -41.1% | 0.60% | −0.43 |
| BHVN Biohaven Ltd. | Reduce -13.9% | 1.24% | −0.42 |
| CABA Cabaletta Bio Inc. | Reduce -65.9% | 0.11% | −0.41 |
| IRTC Irhythm Holdings Inc. | Reduce -85.6% | 0.09% | −0.41 |
| RVMD Revolution Medicines Inc. | Sold out | 0.00% | −0.35 |
| ABBV Abbvie Inc. | Sold out | 0.00% | −0.34 |
| MLTX Moonlake Immunotherapeutics | Sold out | 0.00% | −0.30 |
| TCMD Tactile Systems Technology I | Reduce -93.1% | 0.02% | −0.24 |
| ARVN Arvinas Inc. | Reduce -16.9% | 0.66% | −0.24 |
| MDGL Madrigal Pharmaceuticals Inc. | Reduce -38.5% | 1.79% | −0.23 |
| VRNA Verona Pharma Ltd. | Reduce -35.3% | 0.85% | −0.22 |
| AXGN Axogen Inc. | Reduce -98.0% | 0.01% | −0.22 |
| RCKT Rocket Pharmaceuticals Inc. | Reduce -30.8% | 0.65% | −0.21 |
| RAPT THERAPEUTICS INC | Sold out | 0.00% | −0.19 |
| MORF Morphic Holding Inc. | Sold out | 0.00% | −0.18 |
| PRAX Praxis Precision Medicines I | Reduce -8.7% | 0.75% | −0.13 |
| XENE Xenon Pharmaceuticals Inc. | Reduce -34.6% | 0.55% | −0.13 |
| ENGN Engene Holdings Inc. | Reduce -19.9% | 0.18% | −0.12 |
| COGT Cogent Biosciences Inc. | Sold out | 0.00% | −0.10 |
| IBRX Immunitybio Inc. | Sold out | 0.00% | −0.10 |
| MGNX Macrogenics Inc. | Sold out | 0.00% | −0.10 |
| ESTA Establishment Labs Holdings | Sold out | 0.00% | −0.07 |
| NAMS Newamsterdam Pharma Co. NV | Sold out | 0.00% | −0.07 |
| ISRG Intuitive Surgical Inc. | Reduce -39.3% | 0.66% | −0.05 |
| BBIO Bridgebio Pharma Inc. | Reduce -13.9% | 0.74% | −0.03 |
| KURA Kura Oncology Inc. | Sold out | 0.00% | −0.02 |
| AMLX Amylyx Pharmaceuticals Inc. | Sold out | 0.00% | −0.01 |
| DTIL Precision Biosciences Inc. | Reduce -11.3% | 0.10% | −0.01 |
| ADMA Adma Biologics Inc. | Reduce -56.9% | 0.75% | −0.00 |
| EWTX Edgewise Therapeutics Inc. | Reduce -20.0% | 0.81% | +0.06 |
| NTRA Natera Inc. | Reduce -30.0% | 1.39% | +0.16 |
| NBIX Neurocrine Biosciences Inc. | Reduce -19.2% | 2.16% | +0.20 |
| ACLX Arcellx Inc. | Reduce -1.1% | 5.18% | +0.36 |
| NUVL Nuvalent Inc. Class A | Reduce -8.4% | 4.67% | +0.98 |
| PCVX Vaxcyte Inc. | Reduce -3.6% | 3.39% | +1.07 |
Portfolio Buys Q1 2024 → Q2 2024
| ITCI Intra-Cellular Therapies Inc. | Add +62.6% | 2.84% | +1.55 |
| IMTX Immatics NV | Add +76.5% | 2.27% | +1.42 |
| RYTM Rhythm Pharmaceuticals Inc. | Add +5.5% | 3.42% | +0.92 |
| SLNO Soleno Therapeutics Inc. | Add +4.2% | 3.16% | +0.84 |
| AORT Artivion Inc. | Add +4.7% | 1.73% | +0.73 |
| CTNM Contineum Therapeutics Inc. Class A | New | 0.67% | +0.67 |
| PTGX Protagonist Therapeutics Inc. | Add +27.6% | 1.06% | +0.55 |
| MRUS Merus NV | New | 0.43% | +0.43 |
| RAPP Rapport Therapeutics Inc. | New | 0.42% | +0.42 |
| ACRV Acrivon Therapeutics Inc. | Add +78.2% | 0.75% | +0.37 |
| CGEM Cullinan Therapeutics Inc. | New | 0.32% | +0.32 |
| LIVN Livanova PLC | Add +48.5% | 0.59% | +0.29 |
| INSM Insmed Inc. | New | 0.29% | +0.29 |
| BCYC Bicycle Therapeutics PLC-ADR | New | 0.28% | +0.28 |
| ALDX Aldeyra Therapeutics Inc. | Add +7.9% | 0.74% | +0.25 |
| CNTA Centessa Pharmaceuticals Ltd. | Add +27.6% | 0.86% | +0.24 |
| ICLR Icon PLC | New | 0.24% | +0.24 |
| TEM Tempus AI Inc. Class A | New | 0.23% | +0.23 |
| AKRO Akero Therapeutics Inc. | Add +8.1% | 0.85% | +0.23 |
| ARQT Arcutis Biotherapeutics Inc. | Add +107.8% | 0.35% | +0.22 |
| TYRA Tyra Biosciences Inc. | Add +50.5% | 0.39% | +0.20 |
| ARGX Argenx SE - ADR | New | 0.16% | +0.16 |
| ALLO Allogene Therapeutics Inc. | New | 0.15% | +0.15 |
| ZYME Zymeworks Inc. | Add +55.2% | 0.34% | +0.14 |
| RXRX Recursion Pharmaceuticals-A | New | 0.14% | +0.14 |
| MREO Mereo Biopharma Group PL-ADR | New | 0.11% | +0.11 |
| CRGX Cargo Therapeutics Inc. | Add +6.8% | 1.46% | +0.10 |
| SKYE Skye Bioscience Inc. | New | 0.10% | +0.10 |
| BDSX Biodesix Inc. | New | 0.08% | +0.08 |
| FHTX Foghorn Therapeutics Inc. | New | 0.08% | +0.08 |
| VERU Veru Inc. | Add +26.5% | 0.14% | +0.07 |
| XBI SS SPDR S&P Biotech ETF | New | 0.05% | +0.05 |
| GPCR Structure Therapeutics Inc. | New | 0.03% | +0.03 |
| FATE Fate Therapeutics Inc. | New | 0.03% | +0.03 |
| EGRX Eagle Pharmaceuticals Inc. | New | 0.02% | +0.02 |
| SYRE Spyre Therapeutics Inc. | Add +18.6% | 1.72% | +0.01 |
| IOVA Iovance Biotherapeutics Inc. | Add +34.6% | 5.02% | −0.01 |
| EYPT Eyepoint Inc. | Add +8.6% | 0.13% | −0.08 |
| APGE Apogee Therapeutics Inc. | Add +2.2% | 2.00% | −0.41 |
Options Activity Q1 2024 → Q2 2024
| IRON Disc Medicine Inc. | put | Sold out | 300,000 | $18.7Mbefore exit |
| IMVT Immunovant Inc. | call | Add +100.0% | 200,000 | $5.3M |
| AMLX Amylyx Pharmaceuticals Inc. | call | Sold out | 1,679,125 | $4.8Mbefore exit |
| XBI SS SPDR S&P Biotech ETF | put | Sold out | 50,000 | $4.7Mbefore exit |
| APLT Applied Therapeutics Inc. | call | Sold out | 500,000 | $3.4Mbefore exit |
| AGIO Agios Pharmaceuticals Inc. | call | Sold out | 100,000 | $2.9Mbefore exit |
| FLNA Filana Therapeutics Inc. | put | New | 183,000 | $2.3M |
| NVAX Novavax Inc. | put | Reduce -85.7% | 100,000 | $1.3M |
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 99 | $6.4B | PRAX, SYRE, CELC, ASND, RYTM |
| Q1 2026Amended | 89 | $5.0B | PRAX, CELC, ASND, ROIV, CNTA |
| Q4 2025 | 109 | $5.4B | PRAX, CELC, RYTM, ASND, APGE |
| Q3 2025 | 88 | $3.4B | RYTM, ASND, ACLX, CELC, NUVL |
| Q2 2025 | 80 | $2.7B | VRNA, ASND, ACLX, RYTM, NUVL |
| Q1 2025Amended | 84 | $2.8B | VRNA, ACLX, FOLD, EWTX, RYTM |
| Q4 2024 | 95 | $3.6B | VRNA, ACLX, FOLD, RYTM, NUVL |
| Q3 2024 | 99 | $4.7B | ACLX, NUVL, FOLD, IOVA, PCVX |
| Q2 2024Amended | 104 | $4.1B | CERE, FOLD, ACLX, IOVA, NUVL |
| Q1 2024Amended | 102 | $5.7B | CERE, FOLD, IOVA, ACLX, NUVL |